Skip to main content

ORIGINAL RESEARCH article

Front. Nutr.
Sec. Clinical Nutrition
Volume 11 - 2024 | doi: 10.3389/fnut.2024.1442203
This article is part of the Research Topic Micronutrients, Immunity and Infection View all 17 articles

ClinicaI value of fibroblast growth factor 19 in predicting gastrointestinal dysfunction in patients with sepsis

Provisionally accepted
Linsai Guan Linsai Guan 1Jingni Chen Jingni Chen 2Feiyao Wang Feiyao Wang 2Yanxin Xu Yanxin Xu 2Weixing Zhang Weixing Zhang 2Jianping Zhu Jianping Zhu 2*
  • 1 Shanghai Taikang Shenyuan Rehabilitation Hospital, Shanghai, China
  • 2 Shanghai General Hospital, Shanghai, China

The final, formatted version of the article will be published soon.

    Objective To assess the potential value of fibroblast growth factor 19 (FGF19) as a predictor of gastrointestinal (GI) dysfunction in patients with sepsis. Methods A prospective study was conducted, and 209 patients who were diagnosed with sepsis and admitted to the intensive care unit (ICU) at teaching hospitals in China were enrolled from June 2023 to December 2023. The serum FGF19 level was determined at ICU admission. The differences in serum FGF19 levels between the two groups were compared via the Mann‒Whitney U test, and Spearman’s correlation coefficient was used to identify the correlations of the FGF19 concentration with other clinical variables and biomarkers. Receiver operating characteristic (ROC) analysis was used to determine the value of FGF19 in predicting GI dysfunction in patients with sepsis. Results The total ICU mortality rate was 13.3% (24/180). There was a tendency toward increased ICU mortality in patients with sepsis-associated GI dysfunction compared with patients without GI dysfunction with statistical significance (21.9% vs 8.6%, P=0.031). Serum FGF19 levels were significantly higher in patients with sepsis-associated GI dysfunction than in patients without GI dysfunction [355.1(37.2,2315.4)μg/mL vs 127.4(5.7,944.2)μg/mL,P=0.003]. The results of receiver operating characteristic (ROC) curve analysis revealed that the area under the ROC curve (AUC) for the ability of FGF19 to predict GI dysfunction in patients with sepsis was 0.773(95% CI 0.712~0.827), which was greater than the predictive capacity of PCT [AUC=0.632 (95% CI 0.562~0.804)]. Conclusion Serum FGF19 could be considered as a novel predictor or biomarker of GI dysfunction in patients with sepsis.

    Keywords: Fibroblast growth factor 19 (FGF19), Gastrointestinal dysfunction, Procalcitonin, Sepsis, total bile acid(TBA)

    Received: 01 Jun 2024; Accepted: 27 Aug 2024.

    Copyright: © 2024 Guan, Chen, Wang, Xu, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jianping Zhu, Shanghai General Hospital, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.